Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$154.69 USD

154.69
1,196,999

+4.93 (3.29%)

Updated Nov 4, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?

BIIB vs. ILMN: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina

Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Johnson & Johnson, Cigna, & Vertex

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis

Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.

Illumina (ILMN) Gains But Lags Market: What You Should Know

Illumina (ILMN) closed the most recent trading day at $193.93, moving +0.2% from the previous trading session.

Do Options Traders Know Something About Illumina (ILMN) Stock We Don't?

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

Illumina's (ILMN) GRAIL to Assess Galleri Test With New Deal

Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.

Here's Why Investors Should Retain Illumina (ILMN) Stock Now

Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.

Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI

Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.

Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger

Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.

Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up

Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down

Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.

Illumina (ILMN) Q1 Earnings and Revenues Beat Estimates

Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

QGEN or ILMN: Which Is the Better Value Stock Right Now?

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Illumina (ILMN) Stock For Now

Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

Illumina (ILMN) Launches Genomic Solution Hub in Brazil

Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Here's Why You Should Retain Illumina (ILMN) Stock For Now

Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.

VIR vs. ILMN: Which Stock Should Value Investors Buy Now?

VIR vs. ILMN: Which Stock Is the Better Value Option?

Mark Vickery headshot

Top Research Reports for Merck, Shopify & Intercontinental Exchange

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.